Navigation Links
BD Biosciences Launches BD FACSAria(TM) III Flow Cytometry System
Date:2/23/2010

SAN JOSE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

"As the pioneer in flow cytometry, BD Biosciences' goal is to expand the range of applications that can benefit from this technology by building innovative, powerful tools that are easier to use and more accessible to a larger number of life science researchers," said James Glasscock, President, BD Biosciences – Cell Analysis.  "The new BD FACSAria III system reflects this effort by providing researchers the flexibility to configure a system that meets their application requirements and budgets today, with the ability to expand its capabilities later to meet future needs."

Innovations in the new BD FACSAria III Cell Sorting System include:

  • A next-generation gel coupled cuvette in the flow cell ensures that the system's lasers are focused precisely on the sample stream and that they generate the greatest signal to maximize the amount of emitted light.  Most importantly, it improves collection efficiency and optimizes the resolution needed for multicolor applications, even at high-speed sorting settings.
  • The instrument's advanced optical system works efficiently to maximize signal detection as well as greatly increase the sensitivity and resolution for each color in a multicolor assay. Enhanced sensitivity and resolution helps readily identify and sort dim cell populations.  In addition, the system's next-generation flow cell is designed to improve resolution for side population applications and DNA cell cycle analyses.
  • A new expandable architecture uses an X-mount optical plate that allows the system to be expanded to support up to six laser wavelengths — 633 nm, 561 nm, 488 nm, 445 nm, 405 nm and 375 nm — as well as up to 20 detector positions that can be used simultaneously.
  • A backwards-compatible architecture allows customers to upgrade existing instruments to the new BD FACSAria III platform.  With a field upgrade, laboratories with a BD FACSAria or BD FACSAria II system can upgrade to the new capabilities of the BD FACSAria III system.  

For more information on the BD FACSAria III Cell Sorting System, please visit:  www.bdbiosciences.com/aria

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

SOURCE BD-Becton Dickinson

Back to top

RELATED LINKS
http://www.bd.com

'/>"/>

SOURCE BD-Becton Dickinson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
3. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
4. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
5. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
6. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
9. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
11. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 The pen needles market is ... USD 1.65 billion in 2016, growing at a CAGR ... 2021. Over the years, the pen needles market ... to the growing demand for safety injections in the ... of safety pen needles with an aim to reduce ...
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... 2016 Two new disaster drones delivered telemedical ... mass casualty event Tuesday at John Bell Airport in ... before an audience including Mississippi ... Security, Federal Law Enforcement Agencies, and the United Nations. ... (Health Integrated Rescue Operations), was developed by Italo ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
(Date:12/7/2016)... 3, 2016) , ... (PRWEB) December 07, 2016 ... ... patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, was awarded a ... Mexico with a patient engagement program. New Mexico has more people with cavernous ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... PITTSBURGH, PA (PRWEB) , ... December 06, 2016 , ... ... supportive way to utilize a sling, so she invented the patent-pending SLING-VEST. , The ... doing so, it offers an improved alternative to traditional slings. As a result, it ...
Breaking Medicine News(10 mins):